Kymera Therapeutics Inc. (KYMR)
NASDAQ: KYMRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 108.35 0.00%
KYMR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $8.91B
- EPS (TTM)
- -$3.25
- Dividend yield
- None
- 52-week range
- 55.26 – 130.05
- Day range
- 103.45 – 108.65
- Volume / Avg
- 1.17M / 692.49K
- Beta
- —
- Shares outstanding
- 82.26M
- Next earnings
- Nov 3, 2026
52-week range
KYMR stock today
Kymera Therapeutics (KYMR) closed at $108.35 on Oct 7, up 2.24% (+$2.37), versus the S&P 500's 0.22% decline. Shares are 16.7% below their 52-week high of $130.05, set on Jun 25, 2026 and 96.1% above the 52-week low of $55.26, in the middle of the past year's range. KYMR is up 38.4% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 89.3%.
Kymera Therapeutics has posted a net loss over the last twelve months (EPS of -$3.25), so its P/E ratio is not meaningful. Kymera Therapeutics's next earnings report is expected on Nov 3, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Kymera Therapeutics
Company profileKymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Nello Mainolfi M.D., Ph.D.
- Headquarters
- Watertown, MA
- Employees
- 273
- IPO year
- 2020
- Website
- kymeratx.com
Financial highlights
Full financialsIn fiscal 2025, Kymera Therapeutics generated $39.2 million in revenue, down 16.7% from fiscal 2024, its first annual decline since 2024. Kymera Therapeutics reported a net loss of $311.4 million, compared with a loss of $223.9 million a year earlier. Gross margin was 0.0% (flat year over year) and operating margin -891.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $39.21M | $47.07M | $78.59M | $46.83M | $72.83M |
| Growth | -16.70% | -40.11% | +67.84% | -35.71% | +114.00% |
| Net income | $-311.35M | $-223.86M | $-146.96M | $-154.81M | $-100.22M |
| EPS (diluted) | $-3.69 | $-2.98 | $-2.52 | $-2.87 | $-2.09 |
Analyst forecast
ForecastConsensus (23 analysts)
strong_buy
Avg. price target
$139.32+28.58%
- Strong buy 4
- Buy 17
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 3, 2026
- EPS estimate
- $-1.25
- Last reported (Q2 2026)
- Aug 5, 2026
- EPS actual vs est.
- $-0.62 vs —
KYMR news
All KYMR newsKymera Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| QGENQiagen N.V. | 44.79 | -1.88% | $9.25B | vs KYMR |
| KRYSKrystal Biotech Inc. | 324.57 | -0.69% | $9.61B | vs KYMR |
| PCVXVaxcyte Inc. | 66.96 | +0.39% | $9.96B | vs KYMR |
| TWSTTwist Bioscience Corporation | 155.65 | -6.78% | $10.32B | vs KYMR |
| IBRXImmunityBio Inc. | 9.75 | +0.62% | $10.33B | vs KYMR |
| RGENRepligen Corporation | 167.22 | -4.37% | $10.62B | vs KYMR |
| IMVTImmunovant Inc. | 32.04 | -0.22% | $6.62B | vs KYMR |
| TECHBio-Techne Corp | 72.53 | +0.14% | $11.37B | vs KYMR |
Indexes, lists and sector
Kymera Therapeutics stock FAQ
What is Kymera Therapeutics's stock price today?
KYMR last traded at $108.35 as of Oct 7, 4:00 PM EDT, up 2.24% on the day. Prices are delayed at least 15 minutes.
When is Kymera Therapeutics's next earnings date?
Kymera Therapeutics is expected to report earnings on Tuesday, November 3, 2026. Analysts expect EPS of $-1.25.
Who is Kymera Therapeutics's CEO?
Dr. Nello Mainolfi M.D., Ph.D. is the chief executive officer of Kymera Therapeutics Inc., which has about 273 employees.
What is the KYMR 52-week high?
The 52-week high for KYMR is $130.05 and the 52-week low is $55.26. The stock is currently 16.7% below its high.